Pzena Investment Management LLC Grows Stock Holdings in Koninklijke Philips N.V. $PHG

Pzena Investment Management LLC increased its position in Koninklijke Philips N.V. (NYSE:PHG) by 33.5% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 20,978 shares of the technology company’s stock after acquiring an additional 5,267 shares during the period. Pzena Investment Management LLC’s holdings in Koninklijke Philips were worth $503,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the company. Bessemer Group Inc. raised its stake in Koninklijke Philips by 2,935.4% during the 1st quarter. Bessemer Group Inc. now owns 1,973 shares of the technology company’s stock valued at $51,000 after buying an additional 1,908 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its stake in Koninklijke Philips by 1,170.3% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,439 shares of the technology company’s stock valued at $62,000 after buying an additional 2,247 shares during the last quarter. Blue Trust Inc. raised its stake in Koninklijke Philips by 30.0% during the 2nd quarter. Blue Trust Inc. now owns 4,408 shares of the technology company’s stock valued at $106,000 after buying an additional 1,017 shares during the last quarter. Wealthquest Corp purchased a new stake in Koninklijke Philips during the 1st quarter valued at $116,000. Finally, Allworth Financial LP raised its stake in Koninklijke Philips by 16.2% during the 1st quarter. Allworth Financial LP now owns 4,638 shares of the technology company’s stock valued at $115,000 after buying an additional 645 shares during the last quarter. 13.67% of the stock is currently owned by hedge funds and other institutional investors.

Koninklijke Philips Stock Up 0.7%

Shares of PHG stock opened at $27.53 on Tuesday. The stock has a market cap of $26.51 billion, a P/E ratio of 144.87, a PEG ratio of 0.72 and a beta of 0.82. The company’s fifty day simple moving average is $27.58 and its two-hundred day simple moving average is $25.27. The company has a quick ratio of 0.81, a current ratio of 1.26 and a debt-to-equity ratio of 0.69. Koninklijke Philips N.V. has a 52 week low of $21.48 and a 52 week high of $32.62.

Koninklijke Philips (NYSE:PHG) last issued its earnings results on Tuesday, July 29th. The technology company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.12. Koninklijke Philips had a return on equity of 11.95% and a net margin of 1.00%.The firm had revenue of $5.05 billion for the quarter, compared to analysts’ expectations of $4.35 billion. Analysts predict that Koninklijke Philips N.V. will post 1.63 EPS for the current fiscal year.

Wall Street Analyst Weigh In

PHG has been the subject of a number of research reports. Wall Street Zen lowered shares of Koninklijke Philips from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Weiss Ratings reissued a “sell (d+)” rating on shares of Koninklijke Philips in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy”.

Koninklijke Philips Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.